256353-34-1

Usage

Chemical Properties

Tan solid

InChI:InChI=1/C4H3Cl2NO2S2/c5-2-1-3(10-4(2)6)11(7,8)9/h1H,(H2,7,8,9)

Upstream product

• 126714-85-0 2,3-dichlorothiophene-5-sulfonyl chloride 

Downstream Products

• 861238-35-9 [2H]-DG-041 
• 882996-45-4 4,5-dichlorothiophene-2-sulfonic acid {(E)-3-[1-(2,4-dichloro-benzyl)-2,3-dioxo-2,3-dihydro-1H-indol-7-yl]acryloyl}amide 
• 1138722-35-6 C₂₃H₂₀Cl₄N₂O₄S₂ 
• 1138722-37-8 C₂₃H₂₀Cl₄N₂O₄S₂ 
• 1138722-39-0 C₂₃H₂₁Cl₃N₂O₄S₂ 
• 1138722-41-4 C₂₃H₂₁Cl₂FN₂O₄S₂ 
• 1138722-43-6 C₂₃H₂₀Cl₂F₂N₂O₄S₂ 
• 1138722-45-8 C₂₃H₂₁Cl₂FN₂O₄S₂ 
• 1138722-48-1 C₂₄H₂₄Cl₂N₂O₅S₂ 
• 1138722-90-3 C₂₄H₂₀Cl₂F₂N₂O₆S₂ 
• 1127288-95-2 4,5-dichlorothiophene-2-sulfonic acid {3-[1-(2,4-dichlorobenzyl)-5-fluoro-3-methyl-1H-indol-7-yl]propionyl}amide 

Relevant academic research and scientific papers

2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 2-amino-N-(amino-oxo-aryl-λ6- sulfanylidene)acetamide compounds (referred to herein as ANASIA compounds) that, inter alia, inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase; to treat disorders that are ameliorated by the inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetase; to treat bacterial infections; etc.

PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS

The present invention is related to pyrazine derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.